Loading…
← CockpitCompetitor Analysis › GALT Galectin Therapeutics Inc.Open in the cockpit ↗

Galectin Therapeutics Inc.GALTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum neutral 58
Mkt cap
$301M
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$645,319
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.5%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$2.98
1D+2.4%
1W-9.4%
1M-13.1%
3M-16.5%
6M+34.8%
YTD-28.4%
1Y-50.3%
ATR %9.4%
Beta1.11
52w lowhigh58.2% off high

What Galectin Therapeutics does

Employees: 9

Galectin Therapeutics at a glance

Size Galectin Therapeutics (GALT) is a United States Health Care company (Biotechnology) with a market value of $301M, the 3081st largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.98 on 18 Nov 2026.

Performance Over six months the shares gained 34.8%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026GALT 118Peer median 69
Six months, rebased to 100: Galectin Therapeutics against the median of its 20 peers (local-currency closes).

Galectin Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$87,000-$53,000-$37,000-$33,000-$32,000
EBITDA-$14.7M-$20.0M-$42.4M-$38.0M-$38.3M
Net income-$23.2M-$30.8M-$47.0M-$41.1M-$38.8M
Free cash flow-$14.6M-$23.9M-$41.8M-$33.0M-$31.1M
Capital expenditure$0$0$0$0$0
Total debt$33.3M$134M$106M$71.8M$39.9M

Quarterly statements and history in the cockpit →

Galectin Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%GLSI1873XFOR4894NAUTPROK76306945CCCC2105LRMR358570LYEL086900CRMDCTNM476060GALT6-month return →1-month return →
Up and to the right = strong over both horizons. Galectin Therapeutics is the large dot.

Galectin Therapeutics competitors and peer comparison

How Galectin Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Galectin Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureGALTPeer medianRank in peer set
1-month return-13.1%-4.7%8th lowest of 20
6-month return+34.8%-31.0%highest of 20
Distance from 52-week high-58.2%-52.1%9th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are Galectin Therapeutics's closest peers?
The cockpit's peer set: Greenwich LifeSciences (GLSI), Viva Biotech (1873.HK), X4 Pharmaceuticals (XFOR), Cuorips (4894.T), Nautilus Biotechnolgy (NAUT), ProKidney (PROK), IMPACT Therapeutics (7630.HK), AP Biosciences (6945.TWO).
How has Galectin Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +34.8% against -31.0% for the median peer; over one year -50.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.